AI in medicine. Plus, hot take on Novartis, research credit clash at MD Anderson, testosterone for menopause, and much more!
Happy Friday! Ryan and Alexander here with your STAT “Weekly Update!” We’ve had a busy week and have nothing witty to say, so let’s hop to it…?
AI’s role in medicine
Don't expect artificial intelligence to cure cancer or Alzheimer’s anytime soon.?
Our colleague Casey Ross spoke with academic scientists, pharmaceutical executives and leaders of technology companies to get a better sense of the road ahead for AI in the health tech space. Read the story to see what they had to say.?
Adam’s Take on Novartis
诺华 will eventually walk away from its deal with MorphoSys.?
That is at least what our colleague Adam Feuerstein predicts will happen after the pharmaceutical company announced Monday that it intends to buy MorphoSys for just under $3 billion. His reasoning behind that? Get his full take here.?
And like all good stories, there’s always a sequel. Read Adam’s follow-up here.?
Who gets the research credit?
An early-career kidney researcher accuses Padmanee Sharma at MD Anderson Cancer Center of derailing her career after a dispute over study authorship. Our colleagues Angus Chen and Jonathan Wosen, PhD have the exclusive look into the clash between the junior scientist and the prominent oncologist.?
Using testosterone to treat menopause
“We gender hormones. We say estrogen is for women and testosterone for men. And it’s so narrow-minded and it’s so limiting … If that’s where we’re starting, of course we can’t normalize testosterone for female bodies,” argues Kelly Casperson, a urologist and menopause specialist who treats postmenopausal patients with testosterone.
Testosterone levels decrease with time and reach especially low values after menopause, which can lead to loss of bone density, lower energy, and depression. Some doctors prescribe testosterone as a potential source of relief for such symptoms. Learn more.?
领英推荐
Increased naloxone dosage doesn’t change overdose survival?
Our colleague Lev Facher tells us that people receiving a double dose of naloxone are no more likely to survive an opioid overdose than people receiving a standard, 4-milligram nasal spray … well, he tells us this based off a new study. Find out what else he learned from it.?
15 chairs and only 7 people sitting in them
The Advisory Committee on Immunization Practices, which has in recent years been a 15-person panel, has eight vacancies — one of which dates back more than a year. This committee charged with charting U.S. vaccination policy appears to be atrophying, jeopardizing timely decision-making on how vaccines should be used in this country.
Author picks?
We're going back to a weekend read again for this week's author pick. Our colleague Nicholas Florko uncovered new documents that showed e-cigarette maker Juul spent big $$$ to court Black leaders in promotion of its product. The company even considered renting a suite at Capital One Arena to host Black lawmakers to see Travis Scott's Astroworld Tour. Here's Ryan's pick.?
As someone who’s had Covid multiple times now, understanding long Covid is rather important to me. This week, Liz Cooney looked at new research out of the U.K. seeing if exercise could help treat long Covid. The researchers are working with patients - in a designed trial called REGAIN - to test a way to provide mental health therapy and exercise guidance to people with long Covid without making their conditions worse. See what they found out in ?Alexander’s pick.?
That's all for this week!
As always, feel free to DM us (Ryan Fitzgerald and Alexander Spinelli) and let us know your thoughts on our weekly newsletter!
Join us next week for another edition of "Weekly Update."
If you enjoyed this news roundup, we suggest you subscribe to our flagship newsletter, Morning Rounds, which lands in your inbox every weekday at 6 a.m. ET. You can also sign up for any and all of STAT’s other free newsletters here: https://www.statnews.com/signup/